Twist Bioscience Corporation (TWST) Reports Positive Preclinical Data for SARS-CoV-2 Antibodies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Twist Bioscience Corporation (TWST) Tops Q4 EPS by 16c, Revenues Beat
November 23, 2020 7:25 AM ESTTwist Bioscience Corporation (NASDAQ: TWST) reported Q4 EPS of ($0.54), $0.16 better than the analyst estimate of ($0.70). Revenue for the quarter came in at $32.43 million versus the consensus estimate of $22.67 million.
FISCAL 2020 FOURTH QUARTER FINANCIAL RESULTS
Orders: Total orders received for the fourth quarter of fiscal 2020 were $42.7 million, compared to $20.0 million for the same period of fiscal 2019.Revenue: Total revenues were $32.4 million for the fourth quarter of fiscal 2020 compared to $15.7 million for the same period of fiscal 2019.Cost of Revenues: Cost of revenues for the fourth quarter of fiscal 2020 was $17.6 million... More